NuVasive Valuation
| NUVADelisted Stock | USD 42.35 0.85 1.97% |
At this time, the firm appears to be overvalued. NuVasive secures a last-minute Real Value of $35.07 per share. The latest price of the firm is $42.35. Our model forecasts the value of NuVasive from analyzing the firm fundamentals such as Profit Margin of 0.02 %, return on equity of 0.0331, and Return On Asset of 0.0242 as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that NuVasive's price fluctuation is very steady at this time. Calculation of the real value of NuVasive is based on 3 months time horizon. Increasing NuVasive's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since NuVasive is currently traded on the exchange, buyers and sellers on that exchange determine the market value of NuVasive Stock. However, NuVasive's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 42.35 | Real 35.07 | Hype 42.35 | Naive 43.67 |
The real value of NuVasive Stock, also known as its intrinsic value, is the underlying worth of NuVasive Company, which is reflected in its stock price. It is based on NuVasive's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of NuVasive's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of NuVasive helps investors to forecast how NuVasive stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of NuVasive more accurately as focusing exclusively on NuVasive's fundamentals will not take into account other important factors: NuVasive Total Value Analysis
NuVasive is now anticipated to have valuation of 2.91 B with market capitalization of 2.08 B, debt of 1.01 B, and cash on hands of 225.98 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the NuVasive fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
2.91 B | 2.08 B | 1.01 B | 225.98 M |
NuVasive Investor Information
About 100.0% of the company shares are owned by institutional investors. The book value of NuVasive was now reported as 17.02. The company had not issued any dividends in recent years. Based on the measurements of operating efficiency obtained from NuVasive's historical financial statements, NuVasive is not in a good financial situation at the moment. It has a very high risk of going through financial straits in December.NuVasive Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. NuVasive has an asset utilization ratio of 54.03 percent. This suggests that the Company is making $0.54 for each dollar of assets. An increasing asset utilization means that NuVasive is more efficient with each dollar of assets it utilizes for everyday operations.NuVasive Ownership Allocation
The majority of NuVasive outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in NuVasive to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in NuVasive. Please pay attention to any change in the institutional holdings of NuVasive as this could imply that something significant has changed or is about to change at the company.NuVasive Profitability Analysis
The company reported the previous year's revenue of 1.2 B. Net Income was 40.41 M with profit before overhead, payroll, taxes, and interest of 865.43 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates NuVasive's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in NuVasive and how it compares across the competition.
About NuVasive Valuation
The delisted stock valuation mechanism determines NuVasive's current worth on a weekly basis. Our valuation model uses a comparative analysis of NuVasive. We calculate exposure to NuVasive's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of NuVasive's related companies.NuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. NuVasive, Inc. was incorporated in 1997 and is headquartered in San Diego, California. Nuvasive operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 2900 people.
NuVasive Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 57.4 M | |
| Quarterly Earnings Growth Y O Y | -0.94 | |
| Forward Price Earnings | 17.6991 |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Other Consideration for investing in NuVasive Stock
If you are still planning to invest in NuVasive check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the NuVasive's history and understand the potential risks before investing.
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |